The Valley Desk

NCT04626297 · Interventional trial

A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

Overall registry status Completed

Phase 3

Conditions Atopic Dermatitis

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov